The EPS projection of Argos Therapeutics, Inc. (NASDAQ:ARGS) for quarter ended 2016-09-30 is $-0.4. A week before, the EPS forecast was $-0.4 against target of $-0.4, a month earlier. This estimate stood at $-0.4 60 days earlier versus forecast of $-0.4 90 days earlier, confirming a deviation of 0%.
Argos Therapeutics, Inc. (NASDAQ:ARGS) reported that 18 days ago, the positive EPS revisions were 2 and negative revisions at 0.
In last week, the per-share earnings was lowered 0 times and 0 times positively. In last 120, 60, 30 and 90 days the positive revisions were 2, 3, 0 and 3, respectively.
The downgrade of EPS estimates for Argos Therapeutics, Inc. (NASDAQ:ARGS) in the preceding 120, 60, 30 and 90 days were 0, 0, 0 and 0, in that order.
As per the latest update, for the quarter closed 1, the EPS estimate of Argos Therapeutics, Inc. (NASDAQ:ARGS) was $-0.4. This projection was computed after accounting 3 calls. As reported on 2016-05-12 the EPS was $-0.57. The change was $-0.01, demonstrating a percentage deviation of -1.79%. The projections confirmed a standard deviation of 0.13.
Quarterly Sales Estimates
For the fiscal 2016, the yearly sales target for Argos Therapeutics, Inc. (NASDAQ:ARGS) stands at $1.49 and the median estimate at $0.15. Almost 3 analysts announced their estimates.
The highest estimate is $4.2 while the lowest target is $0.12 showing standard deviation of 2.346%.
As many as 3 analysts released sales estimates reised in upside while 3 reduced sales estimates, demonstrating a deviation of 0%.
In last month, 3 revised sales number projection on upside while 3 lowered the sales target, demonstrating a deviation of 0%.
A quarter ago, 3 hiked sales estimations and 3 reduced sales forecast. Argos Therapeutics, Inc. (NASDAQ:ARGS) stated that the change in forecast was 831.25%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...